CADTH Canadian Drug Expert Committee recommendation: Nitisinone (nitisinone tablets -- Cycle Pharmaceuticals Ltd.) indication : the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine

The CADTH Canadian Drug Expert Committee (CDEC) recommends that nitisinone (nitisinone tablets) be reimbursed for the treatment of adult and pediatric patients with HT-1 in combination with a dietary restriction of tyrosine and phenylalanine

Bibliographic Details

Corporate Authors:	CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2018, August 2018
Edition:	Version 1.0
Series:	CADTH common drug review
Subjects:	Insurance, Health, Reimbursement Canada Tyrosinemias / Drug Therapy Enzyme Inhibitors / Economics Cost-benefit Analysis Cyclohexanones / Therapeutic Use Nitrobenzoates / Therapeutic Use
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK539226
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa